Skip to content
OpenCapital
Get started

Regeneron Pharmaceuticals REGN Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments

Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at other companies

Merck & Co. logo
Merck & Co.MRK
——

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.6%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.1%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$63.95B+17.8%
Enterprise value$63.68B+18.1%
P/E14.5×+2.4×
P/S4.3×+0.4×

Profitability

See full
Gross margin93.9%—
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments?
Regeneron Pharmaceuticals (REGN) reported equity securities without readily determinable fair value - cumulative downward adjustments of $571.6M in Q1 2026.
How has Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments increased by 80.4% year-over-year, from $316.8M to $571.6M.
What is the long-term trend for Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments?
Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's equity securities without readily determinable fair value - cumulative downward adjustments has grown at a 41.3% compound annual growth rate (CAGR), from $59.2M to $334M.